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Introduction
Behavioural adjustment problems in epilepsy, with focus on depression, anxiety, quality of life (QOL), and stigma, have been highlighted in numerous studies. Recent studies confirm a moderate to high frequency of depression (ranging between 19 and 60%) in patients with epilepsy. [1] [2] [3] [4] The rate of mood disorders in epilepsy has been reported to be higher than in other medical conditions, such as diabetes and asthma. 5 Among the most important risk factors for depression in patients with epilepsy are: complex partial seizures, absence of secondary generalized tonic-clonic seizures (GTCS), drug resistance, lack of occupational activity, 4 epileptic focus in the temporal lobe of the dominant hemisphere and neuropsychological evidence of frontal lobe dysfunction, 31, 32 negative impact of anticonvulsant drugs, 10, 34, 40 and psychosocial factors. 35 The prevalence of anxiety disorders in epilepsy has been found to be as high as that of mood disorders, or even higher. Swinkels et al. 1 reported a prevalence of anxiety disorders in epilepsy patients of 25%, and 19% for mood disorders, and in specialist settings, the occurrence of anxiety disorders may exceed 50%. 6, 7 Seizure frequency has been linked with severity of anxiety in some studies, 41 and the risk of anxiety seems to be higher in focal epilepsies than general epilepsies. 42 Some groups have found an association with left temporal lobe involvement. 44 The highest frequency of psychopathology, including both anxiety and depression, is found in patients with persistent refractory epilepsy. 2, 45, 46 In patients with refractory epilepsy, symptoms of depression and seizure worry have been found to be the most important factors affecting QOL. 8 Another major problem for epilepsy patients is stigmatisation, which is reported to be experienced by approximately 50%, and have been correlated with feelings of anxiety, depression and also long-term health problems, injuries and reported side-effects of antiepileptic drugs (AEDs). 9 Approximately 70% of patients with recent onset epilepsy become seizure-free, either without medication or on AEDs. 13, 14 Most studies of behavioural adjustment and QOL have been conducted on patients with active epilepsy (continuing to experience seizures), and relatively few studies have investigated these phenomena in patients with well-controlled epilepsy. Engelberts et al. 11 found that patients with localization-related epilepsy, well-controlled on carbamazepine monotherapy, had unimpaired health-related QOL in comparison with controls matched by age, gender, and education. Uijl et al. 12 conducted a cross-sectional study of subjective complaints in epilepsy patients whose symptoms were well-controlled with AED monotherapy (85%), or polytherapy (15%). QOL was measured by questionnaire (Qoilie-10) and personality traits by Symptom Checklist 90 (SCL-90). Moderate to severe subjective complaints were reported by 67% of these patients on the Qoilie-10 questionnaire. Cognitive complaints were most common, and were primarily associated with AED polytherapy, and high scores on psycho-neuroticism on the SCL-90.
To our knowledge, previous studies have not focused on entirely seizure-free epilepsy patients. Thus, the aim of this study was to describe behavioural function in such a group, and to analyse possible predictors for problems with behavioural adjustment, including age at epilepsy onset, seizure variety, duration of seizure freedom, EEG-findings, MRI pathology, and AED treatment. A subgroup of patients with idiopathic generalized epilepsy (IGE) was described separately; as these have no confounding variables from cerebral lesions and thus may be a good model for studying the effect of epilepsy on behavioural function.
Based on the good cognitive outcome results reported in the study by Hessen et al., 15 which included the same group of seizure-free epilepsy patients as participated in the present study, our main hypothesis was that this group, unlike patients with active epilepsy, would show behavioural adjustments similar to those observed in the general population.
Methods

Selection of patients--inclusion/exclusion criteria
The patients described in the present paper were participants in a large study investigating the withdrawal of AEDs in seizure-free epilepsy patients on monotherapy. They were selected on basis of clinical criteria from the epilepsy registry at the Akershus University Hospital and from six neurological outpatient clinics in the Oslo area: They should have a diagnosis of epilepsy (at least two unprovoked seizures), be between 18 and 67 years old and seizure-free on monotherapy for at least 2 years at the time of inclusion. Excluded were patients with the following characteristics: juvenile myoclonus epilepsy (JME), poly-pharmacy, paroxysmal epileptiform activity in patients with primarily generalized epilepsy, mental retardation, two prior withdrawal attempts, pregnant or seeking pregnancy, progressive neurological disease, other serious disease which may influence the health status of the patient in the study period and co-medication (except post menopausal hormone substitution, antihypertensive, ASA and thyroxin).
Initially, 241 patients seemed to fulfil the inclusion criteria, and were invited to participate in the study. Of these patients, 17 (7%) did not respond to the invitation, 32 (13%) declined to participate, 13 (5%) still had seizures, 20 (8%) fulfilled other exclusion criteria, and 1 had an acute disease. Thus, of the initial 241 patients, 83 (34%) were not eligible or did not wish to participate. The relatively large number of patients that did not wish to participate (32) must be viewed against the background that this study was part of a larger study of AED withdrawal in seizure-free epilepsy patients on monotherapy. Therefore, the patients that declined to participate, primarily did so due to fear of seizure relapse and the potential consequences of seizure relapse (e.g. loss of driver's license). Of the remaining 158 patients, 126 (80%) agreed to answer the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and were included in the present study.
Behavioural assessment
Behavioural function was evaluated with The Norwegian Edition of MMPI-2. 16, 18 Norwegian normative data were used to score data from the MMPI-2. 18 All test results were converted to T-scores, a normally distributed scale with a mean score of 50 and standard deviation (S.D.) of 10. Both the 10 standard clinical scales and the 15 content scales from the MMPI-2 16 were used as outcome measures. Definition of abnormal function was T-scores equal to or greater than 65 on the different subscales.
Statistical analysis
Statistical analyses were performed with the Statistical Package for Social Sciences for Windows (SPSS, version 12.0). First, descriptive statistics of the demographic, clinical and behavioural characteristics of the patient population were computed. Odds ratios for occurrence of abnormal scores on the MMPI-2 were estimated with logistic regression analysis. To assess possible predictors for abnormal scores, variables of importance were tested first in a logistic univariate model, and then in a multivariate logistic model. Behavioural adjustment was dichotomised, with the categories normal and abnormal as the dependent variable. A series of independent t-tests were then performed comparing behavioural function between subgroups of patients defined by clinical variables. As the MMPI-2 subtests are not independent, a Bonferroni correction was not considered appropriate, as this method is highly conservative and has the potential to miss real differences between the groups. 19 
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Results
Demographic and clinical characteristics
Demographic data and clinical information of the 126 study patients are presented in Table 1 . The demographic characteristics of patients with and without IGE were similar. There were no demographic differences between the 158 patients included in our study of cognitive function in seizure-free epilepsy patients 15 and the 126 patients in the present study. Cognitive function was also similar between these two groups of study patients, with the exception of somewhat poorer scores from the patients participating in this study in two tests: delayed visual memory 20 : T = 49.0 versus T = 53.0 ( p = 0.016), and COWA (word fluency) 21 : T = 38.5 versus T = 43.0 ( p = 0.020).
Differences in the groups with and without IGE regarding seizure characteristics, aetiology, and medication are shown in Table 1 . Apart from these differences, the IGE and non-IGE groups were similar, with regard to seizure debut, duration of seizure freedom, epileptiform EEG activity, and AEDs within therapeutic range. The positive MRI-findings in the IGE group were unspecific and not related to the epilepsy.
Behavioural function
Information about behavioural function in the total patient group, and in the groups with and without IGE, is given Table 2 . Profiles of the clinical scales and the content scales for the whole group are shown in Figs. 1 and 2 .
Scores on all the clinical scales and content scales were within the normal range. The scores were close to one standard deviation above the normative mean on the hypochondriasis Behavioural adjustment in seizure-free epilepsy patients 425 Clinical scales L n (%) 34 (27) 27 (27) 7 (29) n.s. F n (%)
22 (18) 19 (19) 3 (13) n.s. K n (%)
11 ( 17 (14) 14 (14) 3 (13) n.s. Social introversion (SI) n (%) 21 (17) 18 (18) 3 (13) n.s.
Content scales Anxiety (ANX) n (%)
18 (14) 13 (13) 5 (21) n.s Fears (FRS) n (%)
18 (14) 15 (15) 3 (13) n.s. Obsessions (OBS) n (%)
14 (11) 12 (12) 
Prediction of abnormally elevated scores on the LSE and work interference (WRK) scales in the total patient sample and for patients with and without IGE
Variables of importance were tested in a logistic univariate model. T-score 65 for all the clinical and content scales were entered individually as dependent variables. The independent variables included MRI pathology, epileptiform activity on EEG, presence of GTCS, presence of IGE, complex partial seizures, epilepsy onset at age <18 years, duration of seizure freedom >5 years, and AED within therapeutic range. Significant predictors for abnormally elevated scores were only demonstrated for the total patient sample, on two of the dependent variables (Table 4) . Multiple regression analysis showed that MRI pathology was a significant predictor for abnormally poor score on the LSE scale (OR = 1.20, p = 0.008), and that epilepsy onset 18 years was a significant predictor of abnormally poor score on the WRK scale (OR = 3.35, p = 0.021).
Discussion
The main findings of the present study were as follows:
(1) The mean scores on the clinical and content scales were within the normal range.
(2) The subscales Hs, D and HEA had group scores close to one standard deviation above the normative mean. (3) Contrary to that which was expected, the percentage of patients with abnormally elevated scores (T 65) were considerably higher than in the normative group being 33% for the D scale, 29% for the HEA scale, 25% for the LSE, 24% for the TRT and 24% for the Hs scale, as compared with 7% in normative group. (4) Multiple regression analysis showed that MRI pathology was a significant predictor for abnormally poor score on the LSE scale and that epilepsy onset 18 years was a significant predictor of abnormally poor score on the WRK scale. (5) A large group of epilepsy patients, who had been seizure-free for a minimum of 2 years, had average durations of education and employment status similar to those of the population mean.
To our knowledge previous studies of behavioural adjustment in epilepsy have not focused on exclusively seizure-free patients. Our study included sufficient patients (n = 126) to enable statistically valid investigation of relationships between medical variables of importance and behavioural function.
The results are relevant for patients that fulfilled the inclusion criteria. There is reason to believe that the patients participating in this study are representative of the majority of seizure-free epilepsy patients, 13, 17 however, the findings are not valid for all seizure-free epilepsy patients, as persons with Behavioural adjustment in seizure-free epilepsy patients 427 poly-pharmacy, 22 paroxysmal epileptiform activity with primarily generalized epilepsy, 23 mental retardation, and progressive neurological disease were excluded from the study.
There has been some contention regarding the validity of MMPI and MMPI-2 in detecting abnormal behaviour in patients with epilepsy. The concern is that patients with epilepsy may have falsely exaggerated MMPI-2 scale scores, due to endorsement of disease-related items. Thus, Nelson et al. 24 suggest cautious interpretation of standard MMPI-2 scores in patients with epilepsy, based on a study of patients with mainly intractable epilepsy. Dikmen et al. 25 however, found that MMPI is sensitive to behavioural abnormalities in patients with different seizure categories. A study by Modrego et al. 26 also supports the validity of MMPI for detection of abnormal behaviour in patients with chronic non-lesional epilepsy. Compared with the Diagnostic and Statistical Manual of Mental Disorders-Version Four (DSM-IV) criteria, the MMPI correctly identified personality disorders, especially depression and paranoid personality. In an overview of behavioural and cognitive assessments in clinical trials of AEDs, Baker and Marson 27 reported that the MMPI was the most commonly used test of behavioural function, and was able to detect changes in more than half of the trials in which it was used. This represents a higher degree of sensitivity than other behavioural methods that have been utilised in clinical trials. Questioning the validity of MMPI-2 in studies of persons with intractable epilepsy or ongoing seizure activity is somewhat irrelevant in the context of this study, as all the patients were seizure-free.
A relatively large proportion of the patients had elevated score (T 65) on the L scale. Scores in this range can be typical for persons who lack insight into their own behaviour, who deny common human faults, or who are trying to create a favourable impression of themselves. Thus, the rather high frequency of elevated L scores may suggest underreporting of problems in the present group of patients. However, the group with T-scores 65 on the L scale (n = 34) and the group with T-scores <65 (n = 92), had similar scores on 9 of the 10 clinical subscales. Significantly lower scores for patients with an elevated L score was only evident on the social introversion (SI) scale, T = 50.4 versus T = 56.5 ( p = 0.009). Consequently, there seems to be no indication that the high occurrence of elevated L scores caused significantly changed scores on the MMPI-2.
On the basis of Norwegian normative data, the mean T-scores for all the clinical and content scales on MMPI-2 were within the normal range. The subscales Hs, D, and HEA had mean scores close to one standard deviation above the normative mean, and the proportion of patients with abnormally elevated scores (T 65) were considerably above the proportion expected based on the normative group. Patients with T-score 65 on the D scale typically exhibit a depressed mood. Patients with scores in the same range on the HS scale are described as excessively concerned about vague physical symptoms, while patients with similar HEA scores are worried about their health, especially with regard to physical symptoms. Abnormally elevated scores on the LSE scale are associated with poor self-esteem, and similar scores on the TRT scale are typical for persons with a negative or pessimistic outlook on treatment possibilities. 28 The high frequency of abnormally elevated scores on these, and other, subscales (Table 3 ) was contrary to expected as based upon the good cognitive outcomes obtained in our previous study of the same patients. 15 The results of the present study may resemble those from studies of patients with active epilepsy, that find moderate to high frequency of depression, [1] [2] [3] [4] seizure worry and reduced QOL, 8 and anxiety. 1, 6, 7 The average duration of education of the patient group was similar to the population mean in Norway, for persons between 30 and 39 years, and 2% of the patients were either receiving disability benefit or had retired, which is less than the expected 6% for a similar age group in Norway. 29 The groups of patients with IGE and the heterogeneous group without IGE had similar education durations and work status.
Although all the mean MMPI-2 scores in this study were within the normal range, the frequency of patients with abnormally elevated scores on several depression-related subscales, were clearly above expected, based on normative data. The literature suggests that neurobiological, 4, 30, 31, 32 iatrogenic, 10, 34, 40 and psychosocial 4,35 dimensions constitute main risk factors for depression in epilepsy. Although the present study does not provide any clear answers regarding risk factors for depression in seizure-free epilepsy patients, the results may indicate some possible clues.
With regard to neurobiological risk factors, depression appears to be elevated in patients with seizures of left temporal lobe origin and with neurophysiological and neuropsychological evidence of frontal lobe dysregulation. 31, 32 However, the theory of left-sided involvement has been challenged by Quiske et al., 33 who found a similar predominance of depressive symptoms in both left and right-sides pathologies. The patients in the present study had been seizure-free for 2 years or more, and were therefore not directly comparable with patients in those studies with patients with persistent seizures and verified neurophysiological and neuropsycholo-gical abnormalities. However, the finding that MRI pathology was a significant predictor for abnormally poor score on the LSE scale does suggest that a depression-related phenomenon, like low selfesteem, may be associated with neurobiological factors in seizure-free epilepsy patients also.
With regard to iatrogenic risk factors for depression, the relationship between AEDs and mood have been discussed, and particularly that phenobarbital has been associated with increased risk of depression in comparison with carbamazepine. 34 In the present study most of the patients were treated with carbamazepine, and only 3 patients received phenobarbital. In the randomised, double-blinded, and placebocontrolled withdrawal study by Hessen et al., 10 based on the same group of patients as in this study, only slightly elevated depression scores were related to the use of AEDs. On the depression scale (DEP) withdrawal resulted in an improvement of 4.1 T-scores ( p = 0.012). Therefore, it is probable that treatment with AEDs contributes slightly to the high frequency of depressed patients, but it seems unlikely that AED treatment alone can explain these results.
With regard to psychosocial risk factors for depression in epilepsy a theme associated with the nature of epilepsy has been discussed in the literature. It involves the fact that patients with epilepsy experience random seizures over which they have minimal control. This has been discussed in the context of the concepts of external locus of control and the concept of learned helplessness, and have been found to apply to the epilepsy-depression relation. 35, 36 Also the perception of stigma, which affects approximately 50% of people with epilepsy 9 have been shown to have a positive relationship with affective disorders. 36 Although the present seizure-free patients probably have less seizure worry, less feeling of external locus of control, and less experience of stigma than patients with persistent seizures, it is probable that these psychosocial elements also have influence on these patients and the rather high frequency of depressive symptoms and health-related concerns. This may be particularly relevant in the study patients that were included in a trial with the aim to withdraw their medication. This is a sensitive situation which may have contributed to the level of seizure worry and health-related concerns.
Early epilepsy onset (18 years) was significantly associated with abnormally poor score on the WRK scale. Scores in this range are typical for persons who report impaired working ability, poor self-confidence, lack of energy, and a tendency to give up easily when facing a problem. 28 It is difficult to explain this finding, and both neurobiological and psychosocial factors may be of relevance. Studies have indicated interruption of brain maturation in epilepsy with seizure debut in childhood. 37, 39 In addition, adverse psychosocial experiences related to seizures and seizure worry during childhood and adolescence may have a negative influence on the development of self-confidence.
Conclusions
Group analysis of epilepsy patients, seizure-free for more than 2 years, found mean MMPI-2 scores within the normal range, and in addition an average duration of education and employment status similar to the population mean. Contrary to expected, the proportion of patients with abnormally elevated scores on scales measuring aspects of depression, health-related concerns, low self-esteem, negative treatment indicators, and physical complaints were clearly above that which would normally be expected. Multiple regression analysis showed that MRI pathology was a significant predictor for an abnormally poor score on the low self-esteem scale, and that epilepsy onset 18 years was a significant predictor of an abnormally poor score on the work interference scale.
